Harmony Biosciences has announced the US Food and Drug Administration (FDA) has approved Wakix (pitolisant) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy.

This makes Wakix the first treatment for the condition not categorised as a controlled substance by the US Drug Enforcement Administration.

Wakix’s approval is based on the results of two multi-centre, randomised, double-blind, placebo-controlled studies – Harmony 1 and Harmony 1bis. In both studies the drug demonstrated a statistically significant improvement in EDS, compared to placebo, as measured on the Epworth Sleepiness Scale (ESS).

The main adverse events were insomnia, nausea and anxiety; these occurred in at least 5% of patients and at twice the rate of the placebo.

Harmony chairman and CEO John C. Jacobs commented: "We are extremely proud to bring WAKIX to market for those living with narcolepsy, a chronic, debilitating, rare neurologic disorder.

"At Harmony we share a vision to develop novel treatment options for people living with rare diseases, with a focus on those that affect the central nervous system. The approval of WAKIX strengthens our commitment to making that vision a reality."

Harmony chief medical officer Jeffrey Dayno said: "The approval of WAKIX provides healthcare professionals managing people living with narcolepsy a new and important treatment option for their patients.

"Additionally, WAKIX is the only non-scheduled treatment option approved for adult patients with narcolepsy, and it offers an important benefit/risk profile to address the unmet medical need that exists in people living with

The drug is a first in class selective histamine 3 receptor antagonist with a novel mechanism of action to increase both the synthesis and release of histamine, a wake-promoting neurotransmitter.

please email: Julia.Zhang@ubmsinoexpo.com